PLK1 and cancer: While it has been thought that colchicine is too toxic for cancer therapy, benzodioxole-containing compounds such as LI, which target colchicine-binding sites, may offer an anti-microtubule therapeutic strategy with reduced side effects, when combined with other drugs such as anti-Plk1 inhibitors.